Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Alferon LDO · 1 trial · 1 indication
Increased expression of genes known to be mediators of interferon response.
| Arm | Type | Description |
|---|---|---|
| 1 | ACTIVE_COMPARATOR | 650 IU |
| 2 | ACTIVE_COMPARATOR | 1300 IU |
| Name | Type | Description |
|---|---|---|
| Alferon LDO | DRUG | - |
Inclusion Criteria: 1. 18-80 years of age. 2. Asymptomatic with close contact within the last 5 days with a person known to have possible SARS (SARS RUI-2 (SARS Report under investigation), RUI-3, RUI-4) or probable SARS or confirmed SARS using the Centers for Disease Control and Prevention (CDC) S...
Alferon LDO is an investigational small molecule being studied for use in Severe Acute Respiratory Syndrome (SARS), an infectious disease. It is currently in Phase 2 clinical development and has not been approved by the FDA.
Alferon LDO is being developed by AIM ImmunoTech Inc., a biopharmaceutical company traded on the stock exchange under the ticker symbol AIM.
Alferon LDO is in Phase 2 clinical development. It is an investigational drug and has not received FDA approval. It is being studied for the treatment of Severe Acute Respiratory Syndrome (SARS).
Alferon LDO has one completed Phase 2 clinical trial, identified as NCT00215826, titled 'Study of Alferon® LDO (Low Dose Oral) in Normal Volunteers'. This trial was conducted in Hong Kong with 10 participants and was active-controlled.
Alferon LDO is a specific formulation of Alferon, referred to as Low Dose Oral (LDO). It is being studied for use in Severe Acute Respiratory Syndrome (SARS) and is currently in Phase 2 clinical development.